In current cancer therapies, the efficacy of RAF and MEK inhibitors has been severely limited by intrinsic and acquired resistances arising from the paradoxical activation or re-activation of RAF/MEK/ERK kinase cascade [57]. This evidence concerns the gene MAP2K7 and cancer.